Cetera Investment Advisers Decreases Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Cetera Investment Advisers trimmed its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 2.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 23,110 shares of the company’s stock after selling 547 shares during the period. Cetera Investment Advisers’ holdings in Invesco Biotechnology & Genome ETF were worth $1,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Gerber Kawasaki Wealth & Investment Management boosted its stake in shares of Invesco Biotechnology & Genome ETF by 3.0% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 223,568 shares of the company’s stock worth $14,874,000 after acquiring an additional 6,527 shares in the last quarter. LPL Financial LLC raised its holdings in Invesco Biotechnology & Genome ETF by 1.7% in the 4th quarter. LPL Financial LLC now owns 92,105 shares of the company’s stock valued at $6,128,000 after acquiring an additional 1,503 shares during the last quarter. Bank of America Corp DE raised its holdings in Invesco Biotechnology & Genome ETF by 3.2% in the 4th quarter. Bank of America Corp DE now owns 68,973 shares of the company’s stock valued at $4,589,000 after acquiring an additional 2,116 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Invesco Biotechnology & Genome ETF by 16.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,002 shares of the company’s stock worth $1,730,000 after acquiring an additional 3,764 shares during the period. Finally, Penobscot Investment Management Company Inc. increased its position in shares of Invesco Biotechnology & Genome ETF by 2.4% during the 4th quarter. Penobscot Investment Management Company Inc. now owns 19,450 shares of the company’s stock worth $1,294,000 after purchasing an additional 450 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of PBE stock opened at $63.34 on Wednesday. The firm’s 50 day moving average price is $61.57 and its 200-day moving average price is $65.97. Invesco Biotechnology & Genome ETF has a one year low of $54.52 and a one year high of $72.84. The firm has a market cap of $224.86 million, a P/E ratio of 21.96 and a beta of 0.79.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.